# Bombay HC quashes FIR against Mylan over Rs 5.96 crore BMC drug deal 2026-08-16T07:45:56+00:00 | Governance | Indian Opinion Desk Corroboration: 1 independent outlet The Bombay High Court has quashed an FIR against pharmaceutical major Mylan Laboratories Ltd over alleged irregularities in the Brihanmumbai Municipal Corporation's purchase of Remdesivir injections during the Covid-19 pandemic. Justice Ashwin Bhobe ruled that the allegations in the FIR, registered at Agripada police station on October 20, 2023, did not disclose a cognizable offence against the company. The FIR followed claims of irregularities in BMC tenders for Remdesivir, with Mylan supplying vials at Rs 650 to Rs 2,626 each, allegedly causing a loss of Rs 5.96 crore to the civic body. Mylan approached the high court arguing that the Maharashtra Lokayukta had already examined similar allegations and, on March 3, 2025, found no corruption and the tender process transparent, attributing price increases to market demand. The court noted the Lokayukta complaint and the FIR were based on identical allegations. Justice Bhobe exercised powers under Section 482 of the CrPC to quash the FIR, observing that continuing criminal proceedings after the Lokayukta's findings would be an abuse of process. ## Coverage - hindustantimes.com This story was synthesised by AI from the source linked above. Tags: BMC, Bombay High Court, Covid-19, Mylan Laboratories, Remdesivir Canonical: https://indianopinion.org/bombay-hc-quashes-fir-against-mylan-over-rs-5-96-crore-bmc-drug-deal/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/bombay-hc-quashes-fir-against-mylan-over-rs-5-96-crore-bmc-drug-deal/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes. How this brief was made: an AI model read the report linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/